NHS vs Private Weight-Loss Treatment in 2026: Who Qualifies & How Long You'll Wait

This is one of the most common questions we get at the pharmacy counter: "can't I just get this free on the NHS?" The honest answer is that both Mounjaro (tirzepatide) and Wegovy (semaglutide) are formally recommended by NICE for weight management — but a NICE recommendation is not the same as being able to walk into your GP and get a prescription. Each medicine runs on its own pathway, with its own criteria, and NHS England is rolling access out in stages rather than to everyone at once.

This guide covers the weight-management indication specifically. A separate, narrower NHS pathway also exists for using semaglutide or tirzepatide to reduce cardiovascular risk in people who already have heart disease — that's a different assessment and outside the scope of this article.

Both sets of criteria carry a lower BMI threshold — usually 2.5 kg/m² less — for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds, in line with NICE's general obesity guidance.

Notice the gap between Mounjaro's full NICE recommendation (BMI 35+ with one condition) and what's actually accessible in primary care right now (BMI 35+ with four conditions). NHS England has been explicit that not everyone who meets the underlying NICE criteria will get access immediately — the wider population is phased in over roughly three years, prioritised by clinical need rather than by whoever asks first.

This is the part patients find most frustrating, and it's worth being upfront about it: the Mounjaro primary-care pathway is optional for GP practices. NHS England has offered practices funding to take part, but not every practice has opted in, and some that have are still building the capacity — extra nursing time, monitoring, follow-up clinics — to deliver it safely at scale. So two people with an identical BMI and identical health conditions can have completely different NHS experiences, purely because of which GP they're registered with.

Wegovy avoids that particular postcode lottery in one sense — it's always a specialist referral, never a direct GP prescription — but Tier 3 services themselves vary hugely in capacity between Integrated Care Boards (ICBs), so the postcode effect simply moves further down the pathway.

There is no single published national waiting time for NHS weight-loss injections, because it is managed locally by each ICB and, for Mounjaro, by each GP practice. What we can say with confidence:

• Tier 3 referral to first assessment is commonly several weeks, but can run much longer where services are under pressure. One ICB (Bristol, North Somerset & South Gloucestershire) funded extra capacity from October 2025 specifically to bring its Tier 3 waiting list under 40 weeks by the end of March 2026 — a useful sign of how long queues can otherwise run in a stretched area.
• Mounjaro via a participating GP practice can, in principle, be near-immediate once you're confirmed eligible — but that depends entirely on your practice having opted in and having capacity, which is not guaranteed anywhere.
• The medicine itself takes months to work. Whichever route you use, both drugs are titrated gradually over weeks, so even a fast NHS start doesn't mean fast results — see our week-by-week side-effect guide for what that titration looks like.

If you don't currently meet the active cohort's criteria at all — say, a BMI of 35 with only two qualifying conditions rather than four — there is, at present, no NHS waiting list to join for Mounjaro in primary care. You would need to wait for a future cohort to widen the criteria, with no published date for when that happens locally.

It's worth being clear about the scale of this: an estimated two million-plus UK adults are currently paying privately for these medicines, against roughly 290,000 receiving them through the NHS — around seven private patients for every one on the NHS. That isn't a criticism of the NHS pathway, it's simply the reality of a phased three-year rollout meeting a much larger demand. Full private pricing for every dose is on our treatments page.

Not sure which medicine or dose would even suit you, NHS or private? Our which treatment guide and suitability checker are a good starting point either way.

Yes, and we help patients do this in both directions. Some start privately to avoid an open-ended wait, then check back with their GP practice periodically in case it later joins the Mounjaro pathway or the eligible cohort widens to include them. Others begin on the NHS and later move to a private pharmacy — for a dose their local service doesn't offer, for the Wegovy pill, or simply because ongoing NHS capacity in their area is limited.

The one rule that matters clinically: never be on two GLP-1 prescriptions from two different prescribers at once. Tell whichever pharmacist or GP you see about any other weight-loss medicine you're taking or have recently stopped — our switching guide sets out how a safe handover works.

WeightGone UK is a GPhC-registered pharmacy (reg. 1118728) in Timperley, Altrincham, serving Sale, Hale, Stretford, Wythenshawe and the wider Greater Manchester area. If the NHS pathway isn't open to you yet — whether that's the current cohort's criteria, your GP practice not offering it, or your local Tier 3 service having a long list — we can usually complete a full face-to-face assessment and start eligible patients within days, not months. Every patient is weighed on the same scales and reviewed in person by the same pharmacist each month, whichever medicine you're on.